secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028506
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX CEO steps down; cash only $0.3M, substantial doubt about going concern
---------------------------------------------------------------------------

- Net loss $2.7M Q2 2023 ($0.07/sh), consistent YoY; cash $0.3M.
- Juvenescence exchanged $36M debt for preferred shares in July 2023; remaining debt $1.2M.
- CEO Michael West stepped down; Joanne Hackett appointed Interim CEO.
- Jean-Christophe Renondin appointed to Board; possible merger with Serina mentioned.
- Company expresses substantial doubt about ability to continue as going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/0001493152-23-028506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer